세계의 애플리버셉트 바이오시밀러 시장 분석 및 예측(2018-2029년)

Global Aflibercept Biosimilars Market Report, History and Forecast 2018-2029

US $ 3,350 ￦ 4,642,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 5,025 ￦ 6,963,000

PDF (Multi User License)

PDF 보고서를 동일 사업장에서 10명까지 이용할 수 있는 라이선스입니다. PDF 내용의 텍스트 등을 Copy & Paste 할 수 있습니다. 인쇄 가능하며, 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,700 ￦ 9,284,000

PDF (Enterprise User License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계의 애플리버셉트 바이오시밀러 시장 규모는 2022년 98억 6,964만 달러에서 2029년까지 103억 9,994만 달러에 이르고, 2023-2029년의 예측 기간에 CAGR 1.41%의 성장이 전망되고 있습니다.

북미 시장은 2022년 76억 3,971만 달러에서 2029년까지 84억 5,936만 달러에 이를 것으로 예측되며, 예측 기간에 연평균 복합 성장률(CAGR)은 1.74%를 나타낼 것으로 예측됩니다.

아시아태평양 시장은 2022년 4억 3,624만 달러에서 2029년까지 3억 8,496만 달러될 전망이며, 예측 기간에 CAGR은 -2.22%를 나타낼 것으로 예측됩니다.

유럽 시장은 2022년 17억 5,349만 달러에서 2029년까지 15억 3,767만 달러에 이를 것으로 예측되며, 예측 기간에 연평균 복합 성장률(CAGR)은 0.78%를 나타낼 것으로 예측됩니다.

세계의 애플리버셉트 바이오시밀러 시장에 대해 조사 분석했으며, 각 지역 시장 규모와 예측, 시장 역학, 경쟁 구도 등에 대한 정보를 제공합니다.

목차

제1장 애플리버셉트 바이오시밀러 시장 개요

• 애플리버셉트 바이오시밀러 제품 개요
• 애플리버셉트 바이오시밀러 시장 : 유형별
  • 2mg
  • 8mg
• 세계의 애플리버셉트 바이오시밀러 시장 규모 : 유형별
  • 세계의 애플리버셉트 바이오시밀러 시장 규모 개요 : 유형별(2018년-2029년)
  • 세계의 애플리버셉트 바이오시밀러 시장 규모 리뷰 : 유형별(2018년-2023년)
  • 세계의 애플리버셉트 바이오시밀러 시장 규모 예측 : 유형별(2024년-2029년)
• 주요 지역 시장 규모 : 유형별
  • 북미의 애플리버셉트 바이오시밀러 매출 내역 : 유형별(2018년-2023년)
  • 유럽의 애플리버셉트 바이오시밀러 매출 내역 : 유형별(2018년-2023년)
  • 아시아태평양의 애플리버셉트 바이오시밀러 매출 내역 : 유형별(2018년-2023년)
  • 라틴아메리카의 애플리버셉트 바이오시밀러 매출 내역 : 유형별(2018년-2023년)
  • 중동 및 아프리카의 애플리버셉트 바이오시밀러 매출 내역 : 유형별(2018년-2023년)

제2장 애플리버셉트 바이오시밀러 시장 경쟁 : 기업별

• 세계 주요 기업 : 애플리버셉트 바이오시밀러 매출별(2018년-2023년)
• 세계 주요 기업 : 애플리버셉트 바이오시밀러 매출별(2018년-2023년)
• 세계 주요 기업 : 애플리버셉트 바이오시밀러 가격별(2018년-2023년)
• 세계의 주요 메이카애플리버셉트 바이오시밀러 제조거점 분포, 판매 지역, 제품 유형
• 애플리버셉트 바이오시밀러 시장 경쟁 구도와 동향
  • 애플리버셉트 바이오시밀러 시장 집중도(2018년-2023년)
  • 세계의 최대 제조업체(2022년 애플리버셉트 바이오시밀러 판매와 매출)
• 세계의 주요 제조업체 : 기업 유형별(Tier 1·Tier 2·Tier 3)(2022년 애플리버셉트 바이오시밀러 매출 기준)
• 주요 제조업체 애플리버셉트 바이오시밀러 시장 진출일
• 주요 제조업체가 제공하는 애플리버셉트 바이오시밀러 제품
• 인수합병(M&A) 및 확대

제3장 애플리버셉트 바이오시밀러 현황과 전망 : 지역별

• 세계의 애플리버셉트 바이오시밀러 시장 규모와 CAGR : 지역별(2018년/2022년/2029년)
• 세계의 애플리버셉트 바이오시밀러 시장 규모 : 지역별
  • 세계의 애플리버셉트 바이오시밀러 판매 수량 양 : 지역별(2018년-2023년)
  • 세계의 애플리버셉트 바이오시밀러 판매 금액 : 지역별(2018년-2023년)
  • 세계의 애플리버셉트 바이오시밀러 판매(수량과 금액), 가격, 총이익(2018년-2023년)
• 세계의 애플리버셉트 바이오시밀러 시장 규모 예측 : 지역별
  • 세계의 애플리버셉트 바이오시밀러 판매 수량 양 : 지역별(2024년-2029년)
  • 세계의 애플리버셉트 바이오시밀러 판매 금액 : 지역별(2024년-2029년)
  • 세계의 애플리버셉트 바이오시밀러 판매(수량과 금액), 가격, 총이익(2024년-2029년)

제4장 애플리버셉트 바이오시밀러 : 용도별

• 애플리버셉트 바이오시밀러 시장 : 용도별
  • 병원
  • 진료소
  • 기타
• 세계의 애플리버셉트 바이오시밀러 시장 규모 : 용도별
  • 세계의 애플리버셉트 바이오시밀러 시장 규모 개요 : 용도별(2018년-2029년)
  • 세계의 애플리버셉트 바이오시밀러 시장 규모 리뷰 : 용도별(2018년-2023년)
  • 세계의 애플리버셉트 바이오시밀러 시장 규모 예측 : 용도별(2024년-2029년)
• 주요 지역 시장 규모 : 용도별
  • 북미의 애플리버셉트 바이오시밀러 매출 내역 : 용도별(2018년-2023년)
  • 유럽의 애플리버셉트 바이오시밀러 매출 내역 : 용도별(2018년-2023년)
  • 아시아태평양의 애플리버셉트 바이오시밀러 매출 내역 : 용도별(2018년-2023년)
  • 라틴아메리카의 애플리버셉트 바이오시밀러 매출 내역 : 용도별(2018년-2023년)
  • 중동 및 아프리카의 애플리버셉트 바이오시밀러 매출 내역 : 용도별(2018년-2023년)

제5장 북미의 애플리버셉트 바이오시밀러 : 국가별

• 북미 애플리버셉트 바이오시밀러 시장 규모 : 국가별
• 북미 애플리버셉트 바이오시밀러 시장 규모 예측 : 국가별

제6장 유럽의 애플리버셉트 바이오시밀러 : 국가별

• 유럽 애플리버셉트 바이오시밀러 시장 규모 : 국가별
• 유럽 애플리버셉트 바이오시밀러 시장 규모 예측 : 국가별

제7장 아시아태평양의 애플리버셉트 바이오시밀러 : 지역별

• 아시아태평양 애플리버셉트 바이오시밀러 시장 규모 : 지역별
• 아시아태평양 애플리버셉트 바이오시밀러 시장 규모 예측 : 지역별

제8장 라틴아메리카의 애플리버셉트 바이오시밀러 : 국가별

• 라틴아메리카 애플리버셉트 바이오시밀러 시장 규모 : 국가별
• 라틴아메리카 애플리버셉트 바이오시밀러 시장 규모 예측 : 국가별

제9장 중동 및 아프리카의 애플리버셉트 바이오시밀러 : 국가별

• 중동 및 아프리카 애플리버셉트 바이오시밀러 시장 규모 : 국가별
• 중동 및 아프리카 애플리버셉트 바이오시밀러 시장 규모 예측 : 국가별

제10장 기업 개요

• Regeneron Pharmaceuticals
• Bayer HealthCare
• Kanghong Pharma
• Biocon
• AbbVie
• Roche
• Novartis
• QILU Pharmaceutical
• Regenxbio
• Samsung Bioepis
• Amgen
• Formycon

제11장 기회, 과제, 리스크, 영향요인 분석

• 애플리버셉트 바이오시밀러 산업 체인 분석
• 애플리버셉트 바이오시밀러 시장 역학
  • 애플리버셉트 바이오시밀러 산업 동향
  • 애플리버셉트 바이오시밀러 시장 성장 촉진요인
  • 애플리버셉트 바이오시밀러 시장이 해결해야 할 과제
  • 애플리버셉트 바이오시밀러 시장 성장 억제요인

제12장 마케팅 전략 분석, 판매업체

• 판매채널
• 애플리버셉트 바이오시밀러 판매업체
• 애플리버셉트 바이오시밀러 다운스트림(Downstream) 고객

제13장 조사 결과와 결론

제14장 부록

LSH

영문 목차

영문목차

The global market for Aflibercept Biosimilars was estimated at US$ 9869.64 million in the year 2022, is projected to reach a revised size of US$ 10399.94 million by 2029, growing at a CAGR of 1.41 % during the forecast period 2023-2029.

North American market for Aflibercept Biosimilars was valued at $ 7639.71 million in 2022 and will reach $ 8459.36 million by 2029, at a CAGR of 1.74 % during the forecast period of 2023 through 2029.

Asia-Pacific market for Aflibercept Biosimilars was valued at $ 436.24million in 2022 and will reach $ 384.96 million by 2029, at a CAGR of -2.22% during the forecast period of 2023 through 2029.

Europe market for Aflibercept Biosimilars was valued at $ 1753.49 million in 2022 and will reach $ 1537.67 million by 2029, at a CAGR of 0.78% during the forecast period of 2023 through 2029.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Aflibercept Biosimilars, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Aflibercept Biosimilars.

The Aflibercept Biosimilars market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Aflibercept Biosimilars market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Aflibercept Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

Market Segmentation

This report covers the Aflibercept Biosimilars segments by manufacturers, by Type, by Application, by region and country, and provides market size (value, volume and average price) and CAGR for the history and forecast period (2018-2022, 2023-2029), considering 2022 as the base year. It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.

By Company

• Regeneron Pharmaceuticals
• Bayer HealthCare
• Kanghong Pharma
• Biocon

Segment by Type

• 2mg
• 8mg

Segment by Application

• Hospitals
• Clinics
• Others

By Region

• North America
  • United States
  • Canada

• Asia-Pacific
  • China
  • Japan
  • South Korea
  • India
  • Australia
  • Southeast Asia

• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Russia

• Latin America
  • Mexico
  • Brazil
  • Argentina
  • Colombia

• Middle East & Africa
  • Turkey
  • Saudi Arabia
  • UAE

Core Chapters

Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, Latin America, Middle East & Africa.

Chapter Two: Detailed analysis of Aflibercept Biosimilars manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter Three: Sales, revenue of Aflibercept Biosimilars in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, Latin America, Middle East & Africa.

Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, sales and revenue by country.

Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter Twelve: Analysis of sales channel, distributors and customers.

Chapter Thirteen: Research Findings and Conclusion.

Table of Contents

1 Aflibercept Biosimilars Market Overview

• 1.1 Aflibercept Biosimilars Product Overview
• 1.2 Aflibercept Biosimilars Market by Type
  • 1.2.1 2mg
  • 1.2.2 8mg
• 1.3 Global Aflibercept Biosimilars Market Size by Type
  • 1.3.1 Global Aflibercept Biosimilars Market Size Overview by Type (2018-2029)
  • 1.3.2 Global Aflibercept Biosimilars Historic Market Size Review by Type (2018-2023)
  • 1.3.3 Global Aflibercept Biosimilars Forecasted Market Size by Type (2024-2029)
• 1.4 Key Regions Market Size by Type
  • 1.4.1 North America Aflibercept Biosimilars Sales Breakdown by Type (2018-2023)
  • 1.4.2 Europe Aflibercept Biosimilars Sales Breakdown by Type (2018-2023)
  • 1.4.3 Asia-Pacific Aflibercept Biosimilars Sales Breakdown by Type (2018-2023)
  • 1.4.4 Latin America Aflibercept Biosimilars Sales Breakdown by Type (2018-2023)
  • 1.4.5 Middle East and Africa Aflibercept Biosimilars Sales Breakdown by Type (2018-2023)

2 Aflibercept Biosimilars Market Competition by Company

• 2.1 Global Top Players by Aflibercept Biosimilars Sales (2018-2023)
• 2.2 Global Top Players by Aflibercept Biosimilars Revenue (2018-2023)
• 2.3 Global Top Players by Aflibercept Biosimilars Price (2018-2023)
• 2.4 Global Top Manufacturers Aflibercept Biosimilars Manufacturing Base Distribution, Sales Area, Product Type
• 2.5 Aflibercept Biosimilars Market Competitive Situation and Trends
  • 2.5.1 Aflibercept Biosimilars Market Concentration Rate (2018-2023)
  • 2.5.2 Global Largest Manufacturers by Aflibercept Biosimilars Sales and Revenue in 2022
• 2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Aflibercept Biosimilars as of 2022)
• 2.7 Date of Key Manufacturers Enter into Aflibercept Biosimilars Market
• 2.8 Key Manufacturers Aflibercept Biosimilars Product Offered
• 2.9 Mergers & Acquisitions, Expansion

3 Aflibercept Biosimilars Status and Outlook by Region

• 3.1 Global Aflibercept Biosimilars Market Size and CAGR by Region: 2018 VS 2022 VS 2029
• 3.2 Global Aflibercept Biosimilars Historic Market Size by Region
  • 3.2.1 Global Aflibercept Biosimilars Sales in Volume by Region (2018-2023)
  • 3.2.2 Global Aflibercept Biosimilars Sales in Value by Region (2018-2023)
  • 3.2.3 Global Aflibercept Biosimilars Sales (Volume & Value), Price and Gross Margin (2018-2023)
• 3.3 Global Aflibercept Biosimilars Forecasted Market Size by Region
  • 3.3.1 Global Aflibercept Biosimilars Sales in Volume by Region (2024-2029)
  • 3.3.2 Global Aflibercept Biosimilars Sales in Value by Region (2024-2029)
  • 3.3.3 Global Aflibercept Biosimilars Sales (Volume & Value), Price and Gross Margin (2024-2029)

4 Aflibercept Biosimilars by Application

• 4.1 Aflibercept Biosimilars Market by Application
  • 4.1.1 Hospitals
  • 4.1.2 Clinics
  • 4.1.3 Others
• 4.2 Global Aflibercept Biosimilars Market Size by Application
  • 4.2.1 Global Aflibercept Biosimilars Market Size Overview by Application (2018-2029)
  • 4.2.2 Global Aflibercept Biosimilars Historic Market Size Review by Application (2018-2023)
  • 4.2.3 Global Aflibercept Biosimilars Forecasted Market Size by Application (2024-2029)
• 4.3 Key Regions Market Size by Application
  • 4.3.1 North America Aflibercept Biosimilars Sales Breakdown by Application (2018-2023)
  • 4.3.2 Europe Aflibercept Biosimilars Sales Breakdown by Application (2018-2023)
  • 4.3.3 Asia-Pacific Aflibercept Biosimilars Sales Breakdown by Application (2018-2023)
  • 4.3.4 Latin America Aflibercept Biosimilars Sales Breakdown by Application (2018-2023)
  • 4.3.5 Middle East and Africa Aflibercept Biosimilars Sales Breakdown by Application (2018-2023)

5 North America Aflibercept Biosimilars by Country

• 5.1 North America Aflibercept Biosimilars Historic Market Size by Country
  • 5.1.1 North America Aflibercept Biosimilars Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
  • 5.1.2 North America Aflibercept Biosimilars Sales in Volume by Country (2018-2023)
  • 5.1.3 North America Aflibercept Biosimilars Sales in Value by Country (2018-2023)
• 5.2 North America Aflibercept Biosimilars Forecasted Market Size by Country
  • 5.2.1 North America Aflibercept Biosimilars Sales in Volume by Country (2024-2029)
  • 5.2.2 North America Aflibercept Biosimilars Sales in Value by Country (2024-2029)

6 Europe Aflibercept Biosimilars by Country

• 6.1 Europe Aflibercept Biosimilars Historic Market Size by Country
  • 6.1.1 Europe Aflibercept Biosimilars Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
  • 6.1.2 Europe Aflibercept Biosimilars Sales in Volume by Country (2018-2023)
  • 6.1.3 Europe Aflibercept Biosimilars Sales in Value by Country (2018-2023)
• 6.2 Europe Aflibercept Biosimilars Forecasted Market Size by Country
  • 6.2.1 Europe Aflibercept Biosimilars Sales in Volume by Country (2024-2029)
  • 6.2.2 Europe Aflibercept Biosimilars Sales in Value by Country (2024-2029)

7 Asia-Pacific Aflibercept Biosimilars by Region

• 7.1 Asia-Pacific Aflibercept Biosimilars Historic Market Size by Region
  • 7.1.1 Asia-Pacific Aflibercept Biosimilars Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
  • 7.1.2 Asia-Pacific Aflibercept Biosimilars Sales in Volume by Region (2018-2023)
  • 7.1.3 Asia-Pacific Aflibercept Biosimilars Sales in Value by Region (2018-2023)
• 7.2 Asia-Pacific Aflibercept Biosimilars Forecasted Market Size by Region
  • 7.2.1 Asia-Pacific Aflibercept Biosimilars Sales in Volume by Region (2024-2029)
  • 7.2.2 Asia-Pacific Aflibercept Biosimilars Sales in Value by Region (2024-2029)

8 Latin America Aflibercept Biosimilars by Country

• 8.1 Latin America Aflibercept Biosimilars Historic Market Size by Country
  • 8.1.1 Latin America Aflibercept Biosimilars Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
  • 8.1.2 Latin America Aflibercept Biosimilars Sales in Volume by Country (2018-2023)
  • 8.1.3 Latin America Aflibercept Biosimilars Sales in Value by Country (2018-2023)
• 8.2 Latin America Aflibercept Biosimilars Forecasted Market Size by Country
  • 8.2.1 Latin America Aflibercept Biosimilars Sales in Volume by Country (2024-2029)
  • 8.2.2 Latin America Aflibercept Biosimilars Sales in Value by Country (2024-2029)

9 Middle East and Africa Aflibercept Biosimilars by Country

• 9.1 Middle East and Africa Aflibercept Biosimilars Historic Market Size by Country
  • 9.1.1 Middle East and Africa Aflibercept Biosimilars Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
  • 9.1.2 Middle East and Africa Aflibercept Biosimilars Sales in Volume by Country (2018-2023)
  • 9.1.3 Middle East and Africa Aflibercept Biosimilars Sales in Value by Country (2018-2023)
• 9.2 Middle East and Africa Aflibercept Biosimilars Forecasted Market Size by Country
  • 9.2.1 Middle East and Africa Aflibercept Biosimilars Sales in Volume by Country (2024-2029)
  • 9.2.2 Middle East and Africa Aflibercept Biosimilars Sales in Value by Country (2024-2029)

10 Company Profiles

• 10.1 Regeneron Pharmaceuticals
  • 10.1.1 Regeneron Pharmaceuticals Company Information
  • 10.1.2 Regeneron Pharmaceuticals Introduction and Business Overview
  • 10.1.3 Regeneron Pharmaceuticals Aflibercept Biosimilars Sales, Revenue and Gross Margin (2018-2023)
  • 10.1.4 Regeneron Pharmaceuticals Aflibercept Biosimilars Products Offered
  • 10.1.5 Regeneron Pharmaceuticals Recent Development
• 10.2 Bayer HealthCare
  • 10.2.1 Bayer HealthCare Company Information
  • 10.2.2 Bayer HealthCare Introduction and Business Overview
  • 10.2.3 Bayer HealthCare Aflibercept Biosimilars Sales, Revenue and Gross Margin (2018-2023)
  • 10.2.4 Bayer HealthCare Aflibercept Biosimilars Products Offered
  • 10.2.5 Bayer HealthCare Recent Development
• 10.3 Kanghong Pharma
  • 10.3.1 Kanghong Pharma Company Information
  • 10.3.2 Kanghong Pharma Introduction and Business Overview
  • 10.3.3 Kanghong Pharma Aflibercept Biosimilars Sales, Revenue and Gross Margin (2018-2023)
  • 10.3.4 Kanghong Pharma Aflibercept Biosimilars Products Offered
  • 10.3.5 Kanghong Pharma Recent Development
• 10.4 Biocon
  • 10.4.1 Biocon Company Information
  • 10.4.2 Biocon Introduction and Business Overview
  • 10.4.3 Biocon Aflibercept Biosimilars Products Offered
  • 10.4.4 Biocon Recent Development
• 10.5 AbbVie
  • 10.5.1 AbbVie Company Information
  • 10.5.2 AbbVie Introduction and Business Overview
  • 10.5.3 AbbVie Aflibercept Biosimilars Products Offered
  • 10.5.4 AbbVie Recent Development
• 10.6 Roche
  • 10.6.1 Roche Company Information
  • 10.6.2 Roche Introduction and Business Overview
  • 10.6.3 Roche Aflibercept Biosimilars Products Offered
  • 10.6.4 Roche Recent Development
• 10.7 Novartis
  • 10.7.1 Novartis Company Information
  • 10.7.2 Novartis Introduction and Business Overview
  • 10.7.3 Novartis Aflibercept Biosimilars Products Offered
  • 10.7.4 Novartis Recent Development
• 10.8 QILU Pharmaceutical
  • 10.8.1 QILU Pharmaceutical Company Information
  • 10.8.2 QILU Pharmaceutical Introduction and Business Overview
  • 10.8.3 QILU Pharmaceutical Aflibercept Biosimilars Products Offered
  • 10.8.4 QILU Pharmaceutical Recent Development
• 10.9 Regenxbio
  • 10.9.1 Regenxbio Company Information
  • 10.9.2 Regenxbio Introduction and Business Overview
  • 10.9.3 Regenxbio Aflibercept Biosimilars Products Offered
  • 10.9.4 Regenxbio Recent Development
• 10.10 Samsung Bioepis
  • 10.10.1 Samsung Bioepis Company Information
  • 10.10.2 Samsung Bioepis Introduction and Business Overview
  • 10.10.3 Samsung Bioepis Aflibercept Biosimilars Products Offered
  • 10.10.4 Samsung Bioepis Recent Development
• 10.11 Amgen
  • 10.11.1 Amgen Company Information
  • 10.11.2 Amgen Introduction and Business Overview
  • 10.11.3 Amgen Aflibercept Biosimilars Products Offered
• 10.12 Formycon
  • 10.12.1 Formycon Company Information
  • 10.12.2 Formycon Introduction and Business Overview
  • 10.12.3 Formycon Aflibercept Biosimilars Products Offered
  • 10.12.4 Formycon Recent Development

11 Opportunities, Challenges, Risks and Influences Factors Analysis

• 11.1 Aflibercept Biosimilars Industrial Chain Analysis
• 11.2 Aflibercept Biosimilars Market Dynamics
  • 11.2.1 Aflibercept Biosimilars Industry Trends
  • 11.2.2 Aflibercept Biosimilars Market Drivers
  • 11.2.3 Aflibercept Biosimilars Market Challenges
  • 11.2.4 Aflibercept Biosimilars Market Restraints

12 Marketing Strategy Analysis, Distributors

• 12.1 Sales Channel
• 12.2 Aflibercept Biosimilars Distributors
• 12.3 Aflibercept Biosimilars Downstream Customers

13 Research Findings and Conclusion

14 Appendix

• 14.1 Research Methodology
  • 14.1.1 Methodology/Research Approach
  • 14.1.2 Data Source
• 14.2 Author Details
• 14.3 Disclaimer

관련자료